# GYRE THERAPEUTICS, INC. (GYRE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from GYRE THERAPEUTICS, INC.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/GYRE/mda/fy2025/): filed 2026-03-13; accession 0001193125-26-106251 (https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/gyre-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/GYRE/mda/fy2024/): filed 2025-03-17; accession 0000950170-25-040279 (https://www.sec.gov/Archives/edgar/data/1124105/000095017025040279/gyre-20241231.htm)
- [FY 2023 MD&A](/company/GYRE/mda/fy2023/): filed 2024-03-27; accession 0000950170-24-037242 (https://www.sec.gov/Archives/edgar/data/1124105/000095017024037242/gyre-20231231.htm)
- [FY 2022 MD&A](/company/GYRE/mda/fy2022/): filed 2023-03-30; accession 0001564590-23-004830 (https://www.sec.gov/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm)
- [FY 2021 MD&A](/company/GYRE/mda/fy2021/): filed 2022-03-31; accession 0001564590-22-012877 (https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-10k_20211231.htm)

Back to /company/GYRE/